Atea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on Tuesday

Posted by Stanley Muller on May 5th, 2026

Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) is expected to be releasing its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect Atea Pharmaceuticals to post earnings of ($0.60) per share and revenue of $22.4190 million for the quarter. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.

Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.08). On average, analysts expect Atea Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Atea Pharmaceuticals Trading Down 0.4%

NASDAQ:AVIR traded down $0.03 during trading hours on Tuesday, hitting $5.68. The stock had a trading volume of 13,182 shares, compared to its average volume of 476,893. Atea Pharmaceuticals has a 1-year low of $2.45 and a 1-year high of $6.45. The company has a market cap of $454.17 million, a PE ratio of -2.94 and a beta of 0.38. The business has a 50 day simple moving average of $5.52 and a two-hundred day simple moving average of $4.20.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Atea Pharmaceuticals in a research report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy”.

Check Out Our Latest Stock Analysis on Atea Pharmaceuticals

Hedge Funds Weigh In On Atea Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in AVIR. Prudential Financial Inc. acquired a new position in Atea Pharmaceuticals in the second quarter worth $36,000. BNP Paribas Financial Markets boosted its holdings in Atea Pharmaceuticals by 57.7% in the third quarter. BNP Paribas Financial Markets now owns 19,913 shares of the company’s stock worth $58,000 after purchasing an additional 7,286 shares during the period. Jump Financial LLC boosted its holdings in Atea Pharmaceuticals by 36.5% in the fourth quarter. Jump Financial LLC now owns 19,113 shares of the company’s stock worth $68,000 after purchasing an additional 5,106 shares during the period. Squarepoint Ops LLC acquired a new position in Atea Pharmaceuticals in the fourth quarter worth $69,000. Finally, Marshall Wace LLP acquired a new position in Atea Pharmaceuticals in the second quarter worth $90,000. Institutional investors and hedge funds own 86.67% of the company’s stock.

About Atea Pharmaceuticals

(Get Free Report)

Atea Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral antiviral therapeutics targeting RNA viruses. The company’s lead program, AT-527, is a direct-acting nucleotide prodrug licensed from Roche and is being evaluated as a potential treatment for coronavirus disease 2019 (COVID-19). In addition to its COVID-19 efforts, Atea’s pipeline includes other small-molecule candidates for hepatitis C virus and emerging RNA pathogens, leveraging its proprietary nucleotide chemistry platform to address significant unmet medical needs in infectious diseases.

Founded in 2014 and headquartered in Cambridge, Massachusetts, Atea operates research laboratories in the Greater Boston area and conducts clinical studies across North America, Europe and parts of Asia.